Next Article in Journal
Potential of Application of Natural Product Nanoparticles in Hypercholesterolemia
Previous Article in Journal
Molecular Docking Study: Application to the Epidermal Growth Factor Receptor
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Proceeding Paper

Synthesis and Supramolecular Organization of para-Carboxyhydrazinylidene Derivative of 3-Nitrophenylthiazolo[3,2-a]pyrimidine †

by
Dilyara O. Mingazhetdinova
1,*,
Artem S. Agarkov
2,
Anna A. Nefedova
2,
Alexander S. Ovsyannikov
2,
Igor A. Litvinov
2,
Svetlana E. Solovieva
1,2 and
Igor S. Antipin
1,2
1
A.M. Butlerov Chemical Institute, Kazan Federal University, 18 Kremlevskaya St., 420008 Kazan, Russia
2
Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzova 8, 420088 Kazan, Russia
*
Author to whom correspondence should be addressed.
Presented at the 28th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-28), 15–30 November 2024; Available online: https://sciforum.net/event/ecsoc-28.
Chem. Proc. 2024, 16(1), 83; https://doi.org/10.3390/ecsoc-28-20101
Published: 14 November 2024

Abstract

:
Synthesis of para-carboxyhydrazinylidene, the derivative of 3-nitrophenylthiazolo[3,2-a]pyrimidine, was successfully performed with good yields. It was established that different types of non-covalent intermolecular interaction may influence the supramolecular motif-synthesized compound. Hydrogen- and chalcogen-bonding supramolecular driving forces collectively impacted the results of two types of the centrosymmetric racemic dimeric self-assembly in crystalline phase.

1. Introduction

The chemistry of heterocyclic compounds is one of the leading areas of organic chemistry. These compounds can serve as the basis for both natural, biologically active substances and synthetic ones. In recent years, thiazolopyrimidines have been of interest because of their properties that can be used in medicine. These include antimicrobial [1], anti-inflammatory [2], analgesic [3], antiviral [4], and anti-tumor effects [3].
Due to their ability to react with electrophilic and nucleophilic reagents, hydrazones are widely used in organic synthesis, particularly in the preparation of heterocyclic compounds.
On the other hand, arylhydrazone derivatives are also promising building blocks for drug design. The chemical properties of the arylhydrazone derivative 1 are quite diverse and the literature provides examples of interactions with reagents of different nature with a C=N-NH fragment. These reactions can be divided into two types of chemical transformations, including (1) alkylation [5] and acylation [6] along the NH nucleophilic center and (2) the formation of new heterocyclic structures, namely the formation of a pyrazole ring in interaction with nitroolefins [7] and acetylenedicarboxylic acid esters (Scheme 1) [8].
The inclusion of functional groups into hydrazone molecules expands their range of applications in organic synthesis. Furthermore, the functionalization of the hydrazone group leads to the production of compounds with unique physical and chemical properties [9].
Hence, the combination of two pharmacophore blocks, namely the thiazolo[3,2-a]pyrimidine platform and arylhydrazone moiety, as part of a single compound is a promising direction for the development of medicinal products. This will expand the library of potentially important systems containing the thiazolopyrimidine fragment.

2. Materials and Methods

NMR experiments were performed on Bruker Avance 500 (Saarbrucken, Germany). Chemical shifts were determined relative to the signals of residual protons of the DMSO-d6. MALDI mass spectra were obtained using an UltraFlex III TOF/TOF spectrometer (Bruker, Bremen, Germany) in the linear mode; p-nitroaniline was used as the matrix. The melting points were determined on a BOETIUS melting table with an RNMK 05 imaging device (VEB MLW Analytik, Dresden, Germany). IR spectra in KBr tablets were recorded on Bruker Vector-22 («Bruker», Germany).
The method of halogen determination is based on the combustion at 1200 °C of organic compounds in oxygen in the presence of a platinum catalyst; the combustion products are adsorbed by the alkali and the halides formed were determined by mercurimetric titration with diphenylcarbazone as an indicator.
CHNS elemental analysis was carried out using a high-temperature one-/two-reactor analyzer (oxidation tube and reduction tube) EuroEA3028-HT-OM («Eurovector SpA», Pavia, Italy).

Synthesis of 4-(2-(6-(Ethoxycarbonyl)-7-methyl-5-(3-nitrophenyl)-3-oxo-5H-thiazolo[3,2-a]pyrimidin-2(3H)-ylidene)hydrazineyl)benzoic acid 8

A solution consisting of sodium nitrite (1 mmol), sodium hydroxide (1 mmol), and para-aminobenzoic acid (1 mmol) in water (3 mL) was added dropwise with stirring at 0–5 °C for 1 h to a cooled solution of hydrochloric acid (5 mmol) in water (5 mL). The resulting solution of aryldiazonium chloride (1 mmol) was added in portions with stirring at 0–5 °C to a cold solution of the corresponding thiazolo[3,2-a]pyrimidine 7 (1 mmol) and sodium acetate (1.1 mmol) in ethanol (10 mL). The mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted with water and the crude product was collected by filtration, washed with water, and crystallized from ethanol.
4-(2-(6-(ethoxycarbonyl)-7-methyl-5-(3-nitrophenyl)-3-oxo-5H-thiazolo[3,2-a]pyrimidin-2(3H)-ylidene)hydrazineyl)benzoic acid 8. Yield 78%, orange powder, mp 256–258 °C. 1H NMR (400 MHz, DMSO-d6, 25 °C) δH ppm: 1.11 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.43 (s, 3H, CH3), 4.00–4.08 (m, 2H, OCH2CH3), 6.16 (s, 1H, CH-Ar), 7.28 (d, J = 7.1 Hz, 2H, CH (Ar)), 7.67–7.71 (m, 1H, CH (Ar)), 7.79–7.80 (m, 1H, CH (Ar)), 7.89 (d, J = 7.1 Hz, 2H, CH (Ar)), 8.12 (m, 1H, CH (Ar)), 8.18–8.20 (m, 1H, CH (Ar)), 11.23 (s, 1H, NH), 12.62 (br. s, 1H, COOH). IR (KBr, cm−1): 3429 (COOH), 3235 (NH); 1722 (C=O); 1704 (C=O); 1543 (C-C(Ph)). MS (MALDI-TOF), m/z, [M − H]: calcd. for C23H19N5O7S: 509.49; found: 507.8. Anal. calcd. for C23H19N5O7S, %: C 54.22; H 3.76; N 13.75; O 21.98, S 6.29. Found C 54.23; H 3.78; N 13.73; S 6.29 (see Figures S1–S3).
Crystals of 8 suitable for an X-ray diffraction study were obtained by slow evaporation of dimethyl sulfoxide (DMSO) solution (20 mL) containing 0.02 mol of the dissolved compound after 5 days. All structures were solved by the direct method using the SHELXT-2018/3 program [10] and refined by the full-matrix least squares method over F2 using the SHELXL-2018/3 program [11]. All calculations were performed using WinGX2021.3 software package [12], the calculation of the geometry of molecules and intermolecular interactions in crystals was carried out using the PLATON program [13], and the drawings of molecules were performed using the ORTEP-3 [12] and MERCURY [14] programs.
Non-hydrogen atoms were refined in the anisotropic approximation. The positions of the hydrogen atoms H(O) were determined using different Fourier maps, and these atoms were refined isotropically. The remaining hydrogen atoms were placed in geometrically calculated positions and included in the refinement in the “riding” model. The crystallographic data of structure 8 were deposited at the Cambridge Crystallographic Data Center, and the registration number and the most important characteristics are given in Table 1.

3. Results and Discussion

4-Carboxyphenylhydrazinylidene derivative of thiazolo[3,2-a]pyrimidine was obtained according to the following Scheme 2. To obtain the initial 1,2,3,4-tetrahydropyrimidine-2-thion 6, a three-component Biginelli reaction was carried out between 3-nitrobenzaldehyde, thiourea, and acetoacetic ether in a molar ratio of 1:1.5:1 by heating the reagents at 120 °C under solvent-free conditions, which led to almost quantitative yields of the product [15]. Precursor for the desired compound was obtained by the interaction of tetrahydropyrimidine-2-thion 6 with ethyl chloroacetate when heated at 110–120 °C [16]. The target product 8 was synthesized by conversion to a base thiazolo[3,2-a]pyrimidine 7 with freshly prepared 4-carboxyphenyldiazonium salt in the presence of sodium acetate. The structure of the obtained compound was characterized by 1H- and IR-spectroscopy, mass-spectrometry, and single-crystal X-ray.
The target arylhydrazone is characterized by the possibility of the existence of azo-hydrazone tautomerism (Scheme 3). A proton signal in the form of a singlet in the weak-field region was registered by 1H NMR spectroscopy (Table 2).
This signal relates to the proton of the NH hydrazone form rather than the proton of the CH azo form, which indicates the formation of only one tautomeric form—the hydrazone.
The crystal for single-crystal X-ray diffraction analysis was obtained by slow evaporation of a solution of 8 in dimethyl sulfoxide (DMSO). The bond lengths of the arylhydrazone fragment are shown in Table 3.
The bond length between the thiazolidine carbon atom C2 and the nitrogen atom N9 is 1.289 (6) Å for crystal 8, the length of the double C=N bond from the literature data is 1.280 Å. This fact confirms the formation of only the hydrazone form. The bond lengths of C2-C3 and N9-N10 of the hydrazone fragment are 1.491 (6) Å and 1.323 (5) Å. Both lengths are shorter compared to the literature for the appropriate single bonds. Meanwhile, the lengths of the double C=N bond are slightly longer than the classical C=N bond. It may be concluded that the conjugation and electron density delocalization occur in this fragment, and two canonical structures contribute to the structure (Scheme 4). The N10-C11 and C14-C15 bond lengths are also shortened, which indicates the conjugation of N10 nitrogen atom lone electron pair with double C=N bond and with 4-carboxyphenyl substituent. The cross-conjugation, and hence a planar form of this fragment including the thiazolidinone cycle and the arylhydrazone fragment, is confirmed by the presented arguments.
Compound 3 was found to be in the Z-configuration with relation to a multiple C=N double bond in the crystalline phase (Figure 1a). Furthermore, only one set of signals was observed in the 1H NMR spectra of 8, indicating the presence of a single geometric isomer in solution. Thus, the diastereoselectivity of the azo-combination reaction with aryldiazonium salt with the formation of the Z-isomer has been proved.
Analyzing the crystal packaging, it was found that two different enantiomers self-organize to form racemic dimers (Figure 2). The driving force of this process was the intermolecular hydrogen OH...O bonding (dO...O = 2.613 Å) due to the interaction of two carboxyl groups of the para-carboxyhydrazinylidene fragment.
Another type of hydrogen bonding was found in crystal 8. It was shown that the formation of a crystalline solvate occurs due to intermolecular hydrogen NH...O type bonding (dN...O = 2.776 Å) with a solvate molecule (Figure 1b).
An interesting fact was the formation of chalcogen S...O bonds between the thiazolidine ring’s sulfur atom and the nitro-group. This supramolecular synthon was the reason for the realization of racemic dimers (Figure 1c).

4. Conclusions

The synthesis of 4-(2-(6-(ethoxycarbonyl)-7-methyl-5-(3-nitrophenyl)-3-oxo-5H-thiazolo[3,2-a]pyrimidin-2(3H)-ylidene)hydrazineyl)benzoic acid was successfully performed with good yields. The combined influence of all the above supramolecular driving forces leads to the implementation of three types of crystal self-assembly, namely racemic hydrogen-, chalcogen-bonded (O-H...O, NH…O, S…O types) dimers. Thus, by controlling the intermolecular interactions, it is possible to influence the supramolecular motif of self-assembly in the crystalline phase. This can play a key role in chiral discrimination for further enantio-separation, the biological activity study, and the production of new supramolecular complexes with promising magnetic and/or adsorption properties.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ecsoc-28-20101/s1, Figure S1: 1H NMR spectrum (500 MHz, DMSO-d6, 25 °C) of 8; Figure S2. MALDI-TOF mass spectrum of 8 (ion polarity: negative); Figure S3: IR spectrum of 8 (KBr tablet).

Author Contributions

Conceptualization, D.O.M., A.S.A., S.E.S. and I.S.A.; methodology, A.S.O. software, I.A.L.; validation, D.O.M. and A.S.A., formal analysis, D.O.M., A.S.A. and A.A.N.; investigation, D.O.M., A.S.A. and A.A.N.; resources, D.O.M. and A.S.A.; data curation, D.O.M., S.E.S. and I.S.A.; writing—original draft preparation, D.O.M.; writing—review and editing, D.O.M., A.S.A., S.E.S. and I.S.A.; visualization, D.O.M.; supervision, A.S.A., S.E.S. and I.S.A.; project administration, A.S.A., S.E.S. and I.S.A.; funding acquisition, A.S.A. and S.E.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by financial support from a government assignment for the Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences (122011800132-5).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Acknowledgments

The authors are grateful to the Assigned Spectral-Analytical Center of Shared Facilities for Study of Structure, Composition and Properties of Substances and Materials of the Federal Research Center of Kazan Scientific Center of Russian Academy of Sciences (CSF-SAC FRC KSC RAS) for technical support.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Youssef, M.M.; Amin, M.A. Microwave assisted synthesis of some new thiazolopyrimidine, thiazolodipyrimidine and thiazolopyrimidothiazolopyrimidine derivatives with potential antioxidant and antimicrobial activity. Molecules 2012, 17, 9652–9667. [Google Scholar] [CrossRef] [PubMed]
  2. Dinakaran, V.S.; Jacob, D.; Mathew, J.E. Synthesis and biological evaluation of novel pyrimidine-2(1H)-ones/thiones as potent anti-inflammatory and anticancer agents. Med. Chem. Res. 2012, 21, 3598–3606. [Google Scholar] [CrossRef]
  3. Tozkoparan, B.; Ertan, M.; Kelicen, P.; Demirdamar, R. Synthesis and anti-inflammatory activities of some thiazolo[3,2-a]pyrimidine derivatives. Farmaco 1999, 54, 588–593. [Google Scholar] [CrossRef]
  4. Belskaya, N.P.; Dehaen, W.; Bakulev, V.A. Synthesis and properties of hydrazones bearing amide, thioamide and amidine functions. Arkivoc 2010, 2010, 275–332. [Google Scholar] [CrossRef]
  5. Ma, C.; Li, Y.; Wen, P.; Yan, R.; Ren, Z.; Huang, G. Copper (I)-catalyzed synthesis of pyrazoles from phenylhydrazones and dialkyl ethylenedicarboxylates in the presence of bases. Synlett 2011, 9, 1321–1323. [Google Scholar] [CrossRef]
  6. Deng, X.; Mani, N.S. Reaction of N-monosubstituted hydrazones with nitroolefins: A novel regioselective pyrazole synthesis. Org. Lett. 2006, 8, 3505–3508. [Google Scholar] [CrossRef] [PubMed]
  7. Michaleviciute, A.; Lygaitis, R.; Andrikaityte, E.; Ostrauskaite, J.; Grazulevicius, J.V.; Jankauskas, V.; Pedisius, N. Charge-transporting 3, 4-ethylenedioxythiophene-based hydrazone monomers and oligomers. Polym. Bull. 2013, 70, 1519–1529. [Google Scholar] [CrossRef]
  8. Johns, S.R.; Lamberton, J.A.; Nelson, E.R. The reaction of formaldehyde arylhydrazones with excess formaldehyde and the acetylation of arylhydrazines. Aust. J. Chem. 1973, 26, 1297–1305. [Google Scholar] [CrossRef]
  9. Shi, C.; Ma, C.; Ma, H.; Zhou, X.; Cao, J.; Fan, Y.; Huang, G. Copper-catalyzed synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles via [3+2] cycloadditions of hydrazones and nitroolefins. Tetrahedron 2016, 72, 4055–4058. [Google Scholar] [CrossRef]
  10. Sheldrick, G.M. Integrated space-group and crystal-structure determination. Acta Crystallogr. Sect. A 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  11. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Crystallogr. Sect. C 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  12. Farrugia, L.J. WinGX and ORTEP for Windows: An update. J. Appl. Crystallogr. 2012, 45, 849–854. [Google Scholar] [CrossRef]
  13. Spek, A.L. Structure validation in chemical crystallography. Acta Crystallogr. Sect. D 2009, 65, 148–155. [Google Scholar] [CrossRef]
  14. Macrae, C.F.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Shields, G.P.; Taylor, R.; Towler, M.; Streek, J.V.D. Mercury: Visualization and analysis of crystal structures. J. Appl. Crystallogr. 2006, 39, 453–457. [Google Scholar] [CrossRef]
  15. Wang, R.; Liu, Z.Q. Solvent-Free and Catalyst-Free Biginelli Reaction To Synthesize Ferrocenoyl Dihydropyrimidine and Kinetic Method To Express Radical-Scavenging Ability. J. Org. Chem. 2012, 77, 3952–3958. [Google Scholar] [CrossRef]
  16. Shiryaev, A.K.; Baranovskaya, N.S.; Eremin, M.S. Synthesis of 5H-thiazolo[3,2-a]pyrimidines. Chem. Heterocycl. Compd. 2013, 48, 1550–1554. [Google Scholar] [CrossRef]
Scheme 1. Chemical properties of arylhydrazone derivatives known in the literature.
Scheme 1. Chemical properties of arylhydrazone derivatives known in the literature.
Chemproc 16 00083 sch001
Scheme 2. Synthesis of 4-(2-(6-(ethoxycarbonyl)-7-methyl-5-(3-nitrophenyl)-3-oxo-5H-thiazolo[3,2-a]pyrimidin-2(3H)-ylidene)hydrazineyl)benzoic acid 8. Reagents and conditions: (a) no solvent; (b) ClCH2CO2Et, 120 °C, no solvent; (c) 4-COOH-C6H4N2+Cl, AcONa, EtOH, 2h, 0–5 °C; *—asymmetric carbon atom.
Scheme 2. Synthesis of 4-(2-(6-(ethoxycarbonyl)-7-methyl-5-(3-nitrophenyl)-3-oxo-5H-thiazolo[3,2-a]pyrimidin-2(3H)-ylidene)hydrazineyl)benzoic acid 8. Reagents and conditions: (a) no solvent; (b) ClCH2CO2Et, 120 °C, no solvent; (c) 4-COOH-C6H4N2+Cl, AcONa, EtOH, 2h, 0–5 °C; *—asymmetric carbon atom.
Chemproc 16 00083 sch002
Scheme 3. Azo-hydrazo-tautomerism.
Scheme 3. Azo-hydrazo-tautomerism.
Chemproc 16 00083 sch003
Scheme 4. Canonical structures of arylhydrazone fragment.
Scheme 4. Canonical structures of arylhydrazone fragment.
Chemproc 16 00083 sch004
Figure 1. ORTEP view of: (a) molecule 8 in the crystalline phase (C, O, N, S, and H-atoms are presented as grey, red, blue, yellow, and light grey ellipsoids with 50% probability, respectively); (b) hydrogen-bonded crystallosolvates 8-DMSO; (c) chalcogen-bonded centrosymmetric racemic dimers of crystal 8 (H-bonds and chalcogen bonds are presented by light blue dotted lines).
Figure 1. ORTEP view of: (a) molecule 8 in the crystalline phase (C, O, N, S, and H-atoms are presented as grey, red, blue, yellow, and light grey ellipsoids with 50% probability, respectively); (b) hydrogen-bonded crystallosolvates 8-DMSO; (c) chalcogen-bonded centrosymmetric racemic dimers of crystal 8 (H-bonds and chalcogen bonds are presented by light blue dotted lines).
Chemproc 16 00083 g001
Figure 2. Hydrogen-bonded centrosymmetric racemic dimers of crystal 8. H-bonds are presented by light blue dotted lines.
Figure 2. Hydrogen-bonded centrosymmetric racemic dimers of crystal 8. H-bonds are presented by light blue dotted lines.
Chemproc 16 00083 g002
Table 1. Crystallographic data for compound 8.
Table 1. Crystallographic data for compound 8.
Compound3
Molecular formulaC23H19N5O7S·C2H6OS
FormulaC23H19N5O7S
Formula Weight587.62
Crystal Systemtriclinic
Space groupP-1
Cell parametersa = 7.875 (3) Å,
b = 17.716 (8) Å,
c = 19.076 (7) Å;
α = 95.852 (14) °
β = 90.594 (18) °
γ = 96.876 (12) °
V [Å3]2627.7 (19)
Z and Z′4 and 0
D(calc) [g/cm3]1.485
λ (Å)0.71073
μ [/mm]0.263
F(000)1224
Theta Min–Max [Deg]0.7178; 0.7457
Reflections measured30,112
Independent reflections12979
Observed reflections [I > 2σ(I)]5734
Goodness of fit1.024
R [I > 2σ(I)]R1 = 0.0720,
wR2 = 0.1968
R (all reflections)R1 = 0.1409,
wR2 = 0.2347
Max. and Min. Resd. Dens. [e/Å−3]0.339 and 0.376
Depositor numbers in CCDC2386559
Table 2. Chemical shifts (ppm) of proton signals in 1H NMR spectra of compound 8.
Table 2. Chemical shifts (ppm) of proton signals in 1H NMR spectra of compound 8.
OCH2CH3CH3OCH2CH3CH-ArCH (Ar) *NHCOOH
1.11 (t)2.43 (s)4.00–4.08 (m)6.16 (s)7.27–8.2011.23 (s)12.62 (br. s)
* The signals of these protons are in the presented region as a number of doublets and multiplets.
Table 3. The bond lengths of the arylhydrazone fragment.
Table 3. The bond lengths of the arylhydrazone fragment.
BondLength (Å)
O3-C3 *1.202 (5)
C2-C31.491 (6)
C2-N91.289 (6)
N9-N101.323 (5)
N10-C111.371 (5)
C14-C151.469 (6)
* See the numbering of atoms in Scheme 1.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mingazhetdinova, D.O.; Agarkov, A.S.; Nefedova, A.A.; Ovsyannikov, A.S.; Litvinov, I.A.; Solovieva, S.E.; Antipin, I.S. Synthesis and Supramolecular Organization of para-Carboxyhydrazinylidene Derivative of 3-Nitrophenylthiazolo[3,2-a]pyrimidine. Chem. Proc. 2024, 16, 83. https://doi.org/10.3390/ecsoc-28-20101

AMA Style

Mingazhetdinova DO, Agarkov AS, Nefedova AA, Ovsyannikov AS, Litvinov IA, Solovieva SE, Antipin IS. Synthesis and Supramolecular Organization of para-Carboxyhydrazinylidene Derivative of 3-Nitrophenylthiazolo[3,2-a]pyrimidine. Chemistry Proceedings. 2024; 16(1):83. https://doi.org/10.3390/ecsoc-28-20101

Chicago/Turabian Style

Mingazhetdinova, Dilyara O., Artem S. Agarkov, Anna A. Nefedova, Alexander S. Ovsyannikov, Igor A. Litvinov, Svetlana E. Solovieva, and Igor S. Antipin. 2024. "Synthesis and Supramolecular Organization of para-Carboxyhydrazinylidene Derivative of 3-Nitrophenylthiazolo[3,2-a]pyrimidine" Chemistry Proceedings 16, no. 1: 83. https://doi.org/10.3390/ecsoc-28-20101

APA Style

Mingazhetdinova, D. O., Agarkov, A. S., Nefedova, A. A., Ovsyannikov, A. S., Litvinov, I. A., Solovieva, S. E., & Antipin, I. S. (2024). Synthesis and Supramolecular Organization of para-Carboxyhydrazinylidene Derivative of 3-Nitrophenylthiazolo[3,2-a]pyrimidine. Chemistry Proceedings, 16(1), 83. https://doi.org/10.3390/ecsoc-28-20101

Article Metrics

Back to TopTop